Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?

Diagnostic and Interventional Imaging

Volumn 95, Issue 3, 2014, Pages 289-300

  Oksuz M O ^a,c   Winter, L ^b   Pfannenberg, C ^c   Reischl, G ^c   Mussig K ^d   Bares, R ^c   Dittmann, H ^c  

^a Hopital Neuchatelois   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Neuroendocrine tumor; PET CT; PRRT

Indexed keywords

IOPROMIDE; RADIOPHARMACEUTICAL AGENT; TETRAXETAN PHENYLALANINE TYROSINE OCTREOTIDE GALLIUM GA 68; TETRAXETAN PHENYLALANINE TYROSINE OCTREOTIDE YTTRIUM Y 90; TUMOR MARKER; UNCLASSIFIED DRUG; 68GA-DOTATATE; ORGANOMETALLIC COMPOUND; SOMATOSTATIN RECEPTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PET SCANNER; RADIOACTIVITY; RADIOISOTOPE THERAPY; TREATMENT RESPONSE; TUMOR GROWTH; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COOPERATION; ENDOVASCULAR SURGERY; INTERDISCIPLINARY COMMUNICATION; MIDDLE AGED; NEUROENDOCRINE TUMORS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; COOPERATIVE BEHAVIOR; ENDOVASCULAR PROCEDURES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERDISCIPLINARY COMMUNICATION; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84900836313     PISSN: None     EISSN: 22115684     Source Type: Journal    
DOI: 10.1016/j.diii.2013.07.006     Document Type: Article

References (49)

1. Gustafsson BI, Siddique L, Chan A, Dong M, Drozdov I, Kidd M,et al. Uncommon cancers of the small intestine, appendix andcolon: an analysis of SEER 1973-2004, and current diagnosis andtherapy. Int J Oncol 2008;33: 1121-31.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 car-cinoid tumors. Cancer 2003;97(4): 934-59.
3. Hemminki K, Li X. Familial carcinoid tumors and subsequentcancers: a nation-wide epidemiologic study from Sweden. IntJ Cancer 2001;94: 444-8.
4. Newton JN, Swerdlow AJ, dos Santos Silva IM, Vessey MP,Grahame-Smith DG, Primatesta P, et al. The epidemiologyof carcinoid tumors in England and Scotland. Br J Cancer 1994;70: 939-42.
5. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastro-entero-pancreatic neuroendocrine tumours: the current incidenceand staging based on the WHO and European Neuroen-docrine Tumour Society classification: an analysis based onprospectively collected parameters. Endocr Relat Cancer 2010;17(4): 909-18, http://dx.doi.org/10.1677/ERC-10-0152.
6. Noronha YS, Raza AS. Well-differentiated neuroendocrine (car-cinoid) tumors of the extrahepatic biliary ducts. Arch PatholLab Med 2010;134: 1075-9.
7. Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinomaof unknown primary site. Semin Oncol 2009;36: 52-9.
8. Reubi JC, Mäcke HR, Krenning EP. Candidates for peptidereceptor radiotherapy today and in the future. J Nucl Med 2005;46(Suppl.), 67S-75S. (Pubitemid 47619021)
9. Oberg K. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors. Expert Rev Anticancer Ther 2009;9: 557-66.
10. Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, MorizaneC, et al. Phase II study of sunitinib in Japanese patientswith unresectable or metastatic, well-differentiated pancre-atic neuroendocrine tumor. Invest New Drugs 2012 [Epub aheadof print].
11. Grozinsky-Glasberg S, Gross DJ. New drugs in the ther-apy of neuroendocrine tumors. J Endocrinol Invest 2012;35(10): 930-6.
12. Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y, et al.Identification of somatostatin receptor subtypes 1, 2A, 3, and5 in neuroendocrine tumors with subtype specific antibodies.Gut 2002;50: 52-60.
13. Van Essen M, Krenning EP, De Jong M, Valkema R, KwekkeboomDJ. Peptide Receptor Radionuclide Therapy with radiolabelledsomatostatin analogues in patients with somatostatin receptorpositive tumors. Acta Oncol 2007;46: 723-34.
14. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment ofadvanced neuroendocrine tumors with radiolabelled somato-statin analogues. Endocr Relat Cancer 2005;12: 683-99.
15. Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dier-ckx RA, et al. Peptide receptor therapies in neuroendocrinetumors. J Endocrinol Invest 2009;32: 360-9.
16. Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment ofneuroendocrine tumours. Endocr Relat Cancer 2011;18(Suppl1):S27-51, http://dx.doi.org/10.1530/ERC-10-0282.
17. Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-BrandJ, Herskind Bruun K, et al. Peptide receptor radionuclidetherapy with Y-DOTATOC and (177)Lu-DOTATOC in advancedneuroendocrine tumors: results from a Danish cohort treatedin Switzerland. Neuroendocrinology 2011;93(3): 189-96.
18. Muros MA, Varsavsky M, Iglesias Rozas P, Valdivia J, Delgado JR,Forrer F, et al. Outcome of treating advanced neuroendocrinetumors with radiolabelled somatostatin analogues. Clin TranslOncol 2009;11: 48-53.
19. Grozinsky-Glasberg S, Barak D, Fraenkel M, Walter MA, Müeller-Brand J, Eckstein J, et al. Peptide receptor radioligand therapyis an effective treatment for the long-term stabilization ofmalignant gastrinomas. Cancer 2011;117(7): 1377-85.
20. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors. Peptide receptor radionuclide ther-apy. Best Pract Res Clin Endocrinol Metab 2007;21: 111-29.
21. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality oflife in patients with gastroenteropancreatic tumors treatedwith [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol 2004;22: 2724-9.
22. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, vanEssen M, Kooij PP, et al. Treatment with the radiolabeledsomatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity,efficacy, and survival. J Clin Oncol 2008;26: 2124-30.
23. Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, GolderW, et al. Prospective, randomized, multicenter trial on theantiproliferative effect of lanreotide, interferon alfa, andtheir combination for therapy of metastatic neuroendocrinegastroenteropancreatic tumors-the International Lanreotideand Interferon Alfa Study Group. J Clin Oncol 2003;21: 2689-96.
24. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de HerderWW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrinegastroenteropancreatic tumors. J Clin Oncol 2005;23: 2754-62.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS,Rubinstein L, et al. New guidelines to evaluate the response totreatment in solid tumors. European Organization for Researchand Treatment of Cancer, National Cancer Institute of theUnited States, National Cancer Institute of Canada. J Natl Can-cer Inst 2000;92: 205-16.
26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, SargentD, Ford R, et al. New response evaluation criteria in solidtumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2): 228-47.
27. O'Donoghue JA, Bardiès M, Wheldon TE. Relationships betweentumor size and curability for uniformly targeted therapy withbeta-emitting radionuclides. J Nucl Med 1995;36: 1902-9.
28. de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ,Kooij PP, et al. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rattumor model is dependent on tumor size. J Nucl Med 2001;42(12): 1841-6.
29. Liu SZ, Zhang YC, Mu Y, Su X, Liu JX. Thymocyte apopto-sis in response to low-dose radiation. Mutat Res 1996;358: 185-91.
30. Oberg K, Jelic S, ESMO Guidelines Working Group. Neu-roendocrine gastroenteropancreatic tumors: ESMO clinicalrecommendations for diagnosis, treatment and follow-up. AnnOncol 2008;19(Suppl. 2):ii104-5.
31. Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, et al.Gallium-68 PET: a new frontier in receptor cancer imaging.Anticancer Res 2007;27: 4087-94.
32. Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T,Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging 2013;40(3): 364-72,http://dx.doi.org/10.1007/s00259-012-2286-6.
33. Gupta SK, Singla S, Bal C. Renal and hematological toxicityin patients of neuroendocrine tumors after peptide recep-tor radionuclide therapy with 177Lu-DOTATATE. Cancer BiotherRadiopharm 2012;27(9): 593-9.
34. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptakeof radiolabeled antibody fragments and peptides for diagnosisand therapy: present status, future prospects and limitations.Eur J Nucl Med 1998;25: 201-12.
35. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelledoctreotide by a combination of lysine and arginine. Eur J NuclMed Mol Imaging 2003;30: 9-15.
36. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H,Razbash AA, et al. Processing of generator-produce68Ga formedical application. J Nucl Med 2007;48: 1741-8.
37. Hanley JA, McNeil BJ. Maximum attainable discriminationand the utilization of radiologic examinations. J Chronic Dis 1982;35: 601-11.
38. Krenning EP, Valkema R, Kwekkeboom DJ, de Herder WW, vanEijck CH, de Jong M, et al. Molecular imaging as in vivo molec-ular pathology for gastroenteropancreatic neuroendocrinetumors: implications for follow-up after therapy. J Nucl Med 2005;46(Suppl. 1), 76S-82S. (Pubitemid 47619022)
39. Kwekkeboom DJ, Krenning EP. Radiolabeled somatostatin ana-log scintigraphy in oncology and immune diseases: an overview.Eur Radiol 1997;7: 1103-9.
40. Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, PlowmanPN, Monson JP, et al. Treatment of advanced neuroen-docrine tumors using combination chemotherapy withlomustine and 5-fluorouracil. Clin Endocrinol 2002;57: 169-83.
41. Waldherr C, Pless M, Maecke HR, Schumacher T, CrazzolaraA, Nitzsche EU, et al. Tumor response and clinical benefit inneuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43: 610-6.
42. Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, PapiS, Lopera Sierra M, et al. 90Y-DOTA-D-Phe1-Try3-octreotidein therapy of neuroendocrine malignancies. Biopolymers 2002;66: 393-8.
43. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB,Pauwels S, Kvols LK, et al. Overview of results of peptidereceptor radionuclide therapy with 3 radiolabeled somato-statin analogs. J Nucl Med 2005;46(Suppl. 1): 62S-6S. (Pubitemid 47619020)
44. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, HaberkornU, Dimitrakopoulou-Strauss A. Comparison of the pharma-cokinetics of 68Ga-DOTATOC and [18F]FDG in patients withmetastatic neuroendocrine tumors scheduled for 90Y-DOTATOCtherapy. Eur J Nucl Med Mol Imaging 2006;33: 1115-22.
45. Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C,Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PETfor assessing response to somatostatin-receptor-mediatedradionuclide therapy. J Nucl Med 2009;50: 1427-34.
46. Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ,Schwaiger M, et al. Correlation of immunohistopathologicalexpression of somatostatin receptor 2 with standardised uptakevalues in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009;36: 48-52.
47. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET andPET/CT: EANM procedure guidelines for tumour PET imaging:version 1.0. Eur J Nucl Med Mol Imaging 2010;37(1): 181-200.
48. Baum RP, Prasad V. Monitoring treatment. In: Cook GJR, MaiseyMN, Britton KE, Chengazi V, editors. Clinical nuclear medicine.4th ed London, UK: Hodder Arnold; 2006. p. 57-78.
49. Oh S, Prasad V, Lee DS, Baum RP. Effect of PeptideReceptor Radionuclide Therapy on somatostatin receptorstatus and glucose metabolism in neuroendocrine tumors:intraindividual comparison of Ga-68 DOTANOC PET/CT andF-18 FDG PET/CT. Int J Mol Imaging 2011;2011: 524130,http://dx.doi.org/10.1155/2011/524130.